Over the last several months, there have been reports that the FDA was considering new warnings for neuronal stabilizing agents (antiseizure medications) that are used not only to treat seizure disorders, but also depression, bipolar disorder, Migraine disease, and other conditions.
After analyzing reports of suicidality (suicidal behavior or ideation [thoughts]), the FDA is requiring all manufacturers of medications in this class to include a new warning on their labeing and develop a...
